Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BCBP | 8-K | neutral | 3/10 | BCB Bancorp dismissed Wolf & Company as its auditor and engaged Deloitte & Touche as its new independent registered publ | Sep 3, 2026 |
| HOFT | 8-K, PRESS-RELEASE | neutral | 2/10 | Hooker Furnishings declared a quarterly cash dividend of $0.115 per share, payable September 30, 2026 to holders of reco | Sep 3, 2026 |
| RAKR | 8-K | bearish | 6/10 | Rainmaker Worldwide issued 9,955,367 shares of restricted common stock to Series A Preferred holders to satisfy $225,020 | Sep 3, 2026 |
| GTBP | 8-K | neutral | 4/10 | GT Biopharma filed a Certificate of Amendment to effect a 1-for-25 reverse stock split and reduce authorized shares from | Sep 3, 2026 |
| RRBI | 8-K | neutral | 3/10 | Red River Bancshares filed an investor presentation for September 2026 conferences, summarizing Q2 2026 results. Net inc | Sep 3, 2026 |
| SMMT | 8-K | bullish | 6/10 | Partner Akeso announced statistically significant overall survival (OS) benefit for ivonescimab monotherapy vs pembroliz | Sep 3, 2026 |
| PLUN | 425, 8-K | bullish | 7/10 | Plutonian Acquisition Corp. II (SPAC) announced a definitive business combination with NT1 Pty Ltd, an Australian minera | Sep 3, 2026 |
| ODFL | 8-K | mixed | 5/10 | Old Dominion Freight Line reported a mid-quarter operating update for Q3 2026, showing revenue per day up 12.4% in Augus | Sep 3, 2026 |
| TSN | 8-K | bearish | 6/10 | Tyson Foods lowered its fiscal 2026 guidance due to significant margin compression in its Beef segment from volatile cat | Sep 3, 2026 |
| CYAB | 8-K | bearish | 7/10 | Cyabra shareholders approved a massive increase in the company's equity incentive plan, raising the share reserve from 2 | Sep 3, 2026 |
| MAX | 8-K, PRESS-RELEASE | bullish | 6/10 | MediaAlpha announced a CFO transition: Pat Thompson steps down effective October 1, 2026, with former CFO Tigran Sinanya | Sep 3, 2026 |
| CARG | 8-K | neutral | 3/10 | CarGurus appointed Matthew Mandel as CFO, effective October 19, 2026, replacing CEO Jason Trevisan who had been serving | Sep 3, 2026 |
| APVO | 424B4, 8-K | mixed | 6/10 | Aptevo Therapeutics filed an 8-K announcing a 93% clinical benefit rate with its mipletamig triplet in frontline AML pat | Sep 3, 2026 |
| WLY | 8-K | neutral | 5/10 | Wiley reported Q1 FY2027 results that were in line with expectations, with adjusted EPS of $0.44 beating the $0.40 conse | Sep 3, 2026 |
| NVDA | 8-K | bullish | 7/10 | NVIDIA announced a definitive agreement to acquire Hugging Face for approximately $11.9 billion in cash to stockholders, | Sep 3, 2026 |
| LBRX | 8-K | neutral | 4/10 | LB Pharmaceuticals appointed Joseph M. Miller as CFO, effective September 2, 2026. Miller brings relevant experience fro | Sep 3, 2026 |
| CXAI | 8-K | bullish | 5/10 | CXApp Inc. (CXAI) received formal notification from Nasdaq confirming it has regained compliance with the minimum $1.00 | Sep 3, 2026 |
| WAMFF | 8-K | neutral | 2/10 | Alaska Silver Corp. granted 375,000 stock options to non-executive directors at C$0.71/share with a five-year term. This | Sep 3, 2026 |
| SURG | 8-K | neutral | 2/10 | SurgePays formed LWP-SURGE, LLC, a Wyoming LLC intended to serve as the vehicle for a proposed joint venture with All Pr | Sep 3, 2026 |
| ORBS | 8-K | bullish | 6/10 | Eightco Holdings disclosed its treasury composition as of September 2, 2026, totaling approximately $380 million, includ | Sep 3, 2026 |
| FFAI | 8-K | neutral | 3/10 | Faraday Future's robotics division, FF AI-Robotics, entered a consulting agreement with AIBOT, a related party, for FCC, | Sep 3, 2026 |
| ABBV | 8-K | neutral | 4/10 | AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology assets zumilokibart | Sep 3, 2026 |
| HFFG | 8-K | bullish | 6/10 | HF Foods Group Inc. completed its acquisition of Searay Foods Inc. and Morgan Foods Inc. for an aggregate base purchase | Sep 3, 2026 |
| APGE | 8-K | bullish | 8/10 | Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion. Sh | Sep 3, 2026 |
| TTC | 8-K | bullish | 6/10 | Toro reported fiscal Q3 2026 results with net sales up 8.4% YoY to $1.23B and adjusted EPS of $1.33, a 1.7% beat vs cons | Sep 3, 2026 |
| MDCX | 8-K | bullish | 7/10 | Medicus Pharma Ltd. (MDCX) entered into a Co-Development and License Agreement with Pfizer Inc. for CD228V, an early cli | Sep 3, 2026 |
| LQDA | 8-K | bullish | 5/10 | Liquidia announced that the FDA granted Fast Track Designation to YUTREPIA (treprostinil) inhalation powder for the trea | Sep 3, 2026 |
| AFJK | 8-K | neutral | 3/10 | Aimei Health Technology Co., Ltd. (AFJK), a blank-check SPAC, filed an 8-K reporting its 22nd monthly extension of the d | Sep 3, 2026 |
| CLYM | 8-K | bullish | 7/10 | Climb Bio announced positive initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy (Ig | Sep 3, 2026 |
| EQBK | 8-K | bullish | 7/10 | Equity Bancshares, Inc. (EQBK) has entered into a definitive agreement to acquire Lincoln Bancorp, the parent company of | Sep 3, 2026 |